Our combination therapeutic trials include IL-15 with intralesional agonistic anti-CD40 to yield tumor specific CD8 T cells, IL-15 with the checkpoint inhibitors, anti-CTLA-4 and anti-PD-L1, and especially IL-15 with cancer directed monoclonal antibodies to increase their ADCC and anticancer efficacy. This evidence concerns the gene CD274 and neoplasm.